Original Research

Published on 02 May 2024

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination

in Vaccines and Molecular Therapeutics

Hakjun Hyun
Eliel Nham
Hye Seong
Jin Gu Yoon
Ji Yun Noh
Hee Jin Cheong
Woo Joo Kim
Sun Kyung Yoon
Se-Jin Park
WonSeok Gwak

Frontiers in Immunology

doi 10.3389/fimmu.2024.1385135

1,670 views
1 citation

Perspective

Published on 02 May 2024

Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity

in Vaccines and Molecular Therapeutics

Raymund R. Razonable

Frontiers in Immunology

doi 10.3389/fimmu.2024.1397040

2,497 views
1 citation

Original Research

Published on 01 May 2024

Antibodies to Aedes aegypti D7L salivary proteins as a new serological tool to estimate human exposure to Aedes mosquitoes

in Vaccines and Molecular Therapeutics

Sophana Chea
Laura Willen
Sreynik Nhek
Piseth Ly
Kristina Tang
James Oristian
Roberto Salas-Carrillo
Aiyana Ponce
Paola Carolina Valenzuela Leon
Dara Kong

Frontiers in Immunology

doi 10.3389/fimmu.2024.1368066

2,938 views

Original Research

Published on 30 Apr 2024

A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine

in Vaccines and Molecular Therapeutics

Xingxing Li
Qinhua Peng
Xinyu Liu
Hongshan Xu
Jingjing Liu
Xiaohong Wu
Qiang Ye
Min Li
Yuhua Li

Frontiers in Immunology

doi 10.3389/fimmu.2024.1374486

1,612 views

Original Research

Published on 30 Apr 2024

A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study

in Vaccines and Molecular Therapeutics

Yutaro Yamamoto
Camila Fabbri
Daiki Okuhara
Rina Takagi
Yuna Kawabata
Takuto Katayama
Mitsuhiro Iyori
Ammar A. Hasyim
Akihiko Sakamoto
Hiroaki Mizukami

Frontiers in Immunology

doi 10.3389/fimmu.2024.1372584

1,606 views
1 citation

Original Research

Published on 30 Apr 2024

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

in Vaccines and Molecular Therapeutics

Yujia Jiang
Rong Wang
Jiazheng Guo
Kexuan Cheng
Lei Chen
Xi Wang
Yating Li
Peng Du
Chen Gao
Jiansheng Lu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1380694

1,235 views
1 citation

Original Research

Published on 29 Apr 2024

Saccharomyces cerevisiae oral immunization in mice using multi-antigen of the African swine fever virus elicits a robust immune response

in Vaccines and Molecular Therapeutics

Shuo Gao
Wenfeng Zuo
Chao Kang
Zhong Zou
Kaiqi Zhang
Jun Qiu
Xiaomin Shang
Jingjing Li
Yuanfeng Zhang
Qi Zuo

Frontiers in Immunology

doi 10.3389/fimmu.2024.1373656

3,618 views

Original Research

Published on 24 Apr 2024

A conserved motif in the immune-subdominant RAP-1 related antigen of Babesia bovis contains a B-cell epitope recognized by antibodies from protected cattle

in Vaccines and Molecular Therapeutics

Manuel J. Rojas
Reginaldo G. Bastos
Jinna Navas
Jacob M. Laughery
Paul A. Lacy
Carlos E. Suarez

Frontiers in Immunology

doi 10.3389/fimmu.2024.1380660

1,467 views
1 citation

Methods

Published on 24 Apr 2024

Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens

in Vaccines and Molecular Therapeutics

Michail Angelos Pavlidis
Nadia Viborg
Mads Lausen
Birgitte Rønø
Daniela Kleine-Kohlbrecher

Frontiers in Immunology

doi 10.3389/fimmu.2024.1404121

1,517 views

Mini Review

Published on 23 Apr 2024

Maintenance of homeostasis by TLR4 ligands

in Vaccines and Molecular Therapeutics

Masataka Oda
Hirofumi Yamamoto
Takashige Kawakami

Frontiers in Immunology

doi 10.3389/fimmu.2024.1286270

1,349 views

Original Research

Published on 22 Apr 2024

Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice

in Vaccines and Molecular Therapeutics

Sonia Jangra
Alexander Lamoot
Gagandeep Singh
Gabriel Laghlali
Yong Chen
Tingting Ye
Adolfo García-Sastre
Bruno G. De Geest
Michael Schotsaert

Frontiers in Immunology

doi 10.3389/fimmu.2024.1370564

2,571 views

Editorial

Published on 18 Apr 2024

Editorial: Precision vaccinology for infectious diseases

in Vaccines and Molecular Therapeutics

Mahbuba Rahman
Mehdi Adeli
Herb E. Schellhorn
Puthen Veettil Jithesh
Ofer Levy

Frontiers in Immunology

doi 10.3389/fimmu.2024.1400443

1,171 views

Original Research

Published on 18 Apr 2024

Rapid generation of human recombinant monoclonal antibodies from antibody-secreting cells using ferrofluid-based technology

in Vaccines and Molecular Therapeutics

Veronica Strazza
Marco Rossi
Andrea Avati
Giusy Tiseo
Marco Falcone
Maria Grazia Cusi
Francesco Menichetti
Paola Ricciardi-Castagnoli
Cristina Tinti
Piero Pileri

Frontiers in Immunology

doi 10.3389/fimmu.2024.1341389

2,558 views
1 citation

Original Research

Published on 18 Apr 2024

Development of a nano-emulsion based multivalent protein subunit vaccine against Pseudomonas aeruginosa

in Vaccines and Molecular Therapeutics

Debaki R. Howlader
Rahul Shubhra Mandal
Ti Lu
Suhrid Maiti
Zackary K. Dietz
Sayan Das
Sean K. Whittier
Aaron C. Nagel
Satabdi Biswas
David J. Varisco

Frontiers in Immunology

doi 10.3389/fimmu.2024.1372349

2,308 views

Clinical Trial

Published on 17 Apr 2024

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

in Vaccines and Molecular Therapeutics

Garyfallia Poulakou
Pierre-Joseph Royer
Nikolay Evgeniev
Gwénaëlle Evanno
Françoise Shneiker
Anne-Geneviève Marcelin
Bernard Vanhove
Odile Duvaux
Stéphane Marot
Vincent Calvez

Frontiers in Immunology

doi 10.3389/fimmu.2024.1330178

1,228 views

Original Research

Published on 16 Apr 2024

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

in Vaccines and Molecular Therapeutics

Elena P. Mazunina
Vladimir A. Gushchin
Denis A. Kleymenov
Andrei E. Siniavin
Elena I. Burtseva
Maksim M. Shmarov
Evgenya A. Mukasheva
Evgeniia N. Bykonia
Sofia R. Kozlova
Elina A. Evgrafova

Frontiers in Immunology

doi 10.3389/fimmu.2024.1381508

2,994 views
1 citation

Navigation group

Articles

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination

Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity

Antibodies to Aedes aegypti D7L salivary proteins as a new serological tool to estimate human exposure to Aedes mosquitoes

A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine

A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

Saccharomyces cerevisiae oral immunization in mice using multi-antigen of the African swine fever virus elicits a robust immune response

A conserved motif in the immune-subdominant RAP-1 related antigen of Babesia bovis contains a B-cell epitope recognized by antibodies from protected cattle

Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens

Maintenance of homeostasis by TLR4 ligands

Lipid nanoparticle composition for adjuvant formulation modulates disease after influenza virus infection in quadrivalent influenza vaccine vaccinated mice

Editorial: Precision vaccinology for infectious diseases

Rapid generation of human recombinant monoclonal antibodies from antibody-secreting cells using ferrofluid-based technology

Development of a nano-emulsion based multivalent protein subunit vaccine against Pseudomonas aeruginosa

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response